Stock BXPHARMA BEXIMCO PHARMACEUTICALS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Beximco Pharmaceuticals Limited

Equities

BXPHARMA

BD0453BXPH04

End-of-day quote Dhaka S.E.
Other stock markets
 06:00:00 2024-07-01 pm EDT 		5-day change 1st Jan Change
121 BDT +2.46% Intraday chart for Beximco Pharmaceuticals Limited +14.69% -17.24%
Apr. 30 EARNINGS AND TRADING: Software Circle & Beximco report higher revenue AN
Apr. 30 Beximco Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024 CI

Strengths

  • Its low valuation, with P/E ratio at 9.6 and 7.82 for the ongoing fiscal year and 2025 respectively, makes the stock pretty attractive with regard to earnings multiples.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
  • The opinion of analysts covering the stock has improved over the past four months.
  • There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
BEXIMCO PHARMACEUTICALS LIMITED Stock Beximco Pharmaceuticals Limited
-17.24% 448M -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+55.55% 823B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+42.31% 641B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.83% 352B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+17.15% 324B
B-
ABBVIE INC. Stock AbbVie Inc.
+7.09% 301B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+14.02% 241B
B+
ROCHE HOLDING AG Stock Roche Holding AG
+1.64% 223B
A+
NOVARTIS AG Stock Novartis AG
+13.66% 218B
B-
AMGEN INC. Stock Amgen Inc.
+7.87% 167B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
-
Profitability
Finances
-

Valuation

P/E ratio
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
-
Divergence of Target Price
Earnings quality
  1. Stock Market
  2. Equities
  3. BXPHARMA Stock
  4. Ratings Beximco Pharmaceuticals Limited